JPWO2021177438A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021177438A5 JPWO2021177438A5 JP2022504474A JP2022504474A JPWO2021177438A5 JP WO2021177438 A5 JPWO2021177438 A5 JP WO2021177438A5 JP 2022504474 A JP2022504474 A JP 2022504474A JP 2022504474 A JP2022504474 A JP 2022504474A JP WO2021177438 A5 JPWO2021177438 A5 JP WO2021177438A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antibody
- set forth
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024206626A JP2025023046A (ja) | 2020-03-06 | 2024-11-27 | 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020038983 | 2020-03-06 | ||
| PCT/JP2021/008635 WO2021177438A1 (ja) | 2020-03-06 | 2021-03-05 | 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206626A Division JP2025023046A (ja) | 2020-03-06 | 2024-11-27 | 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021177438A1 JPWO2021177438A1 (https=) | 2021-09-10 |
| JPWO2021177438A5 true JPWO2021177438A5 (https=) | 2023-01-31 |
Family
ID=77614077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504474A Ceased JPWO2021177438A1 (https=) | 2020-03-06 | 2021-03-05 | |
| JP2024206626A Pending JP2025023046A (ja) | 2020-03-06 | 2024-11-27 | 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024206626A Pending JP2025023046A (ja) | 2020-03-06 | 2024-11-27 | 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230330248A1 (https=) |
| EP (1) | EP4115909A4 (https=) |
| JP (2) | JPWO2021177438A1 (https=) |
| KR (1) | KR20220151630A (https=) |
| CN (1) | CN115209921B (https=) |
| AU (2) | AU2021230226B2 (https=) |
| BR (1) | BR112022015283A2 (https=) |
| CA (1) | CA3168368A1 (https=) |
| CO (1) | CO2022013971A2 (https=) |
| IL (1) | IL296124A (https=) |
| MX (1) | MX2022009597A (https=) |
| NZ (1) | NZ791969A (https=) |
| PH (1) | PH12022551961A1 (https=) |
| TW (2) | TWI906966B (https=) |
| WO (1) | WO2021177438A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| TW202342106A (zh) | 2022-02-09 | 2023-11-01 | 日商第一三共股份有限公司 | 環境應答性遮蔽抗體及其利用 |
| CN118804983A (zh) | 2022-03-02 | 2024-10-18 | 第一三共株式会社 | 含Fc分子的制造方法 |
| JP2025166269A (ja) * | 2022-07-29 | 2025-11-06 | 第一三共株式会社 | 抗腫瘍効果を有する抗体薬物複合体の新規製造方法 |
| KR20250054799A (ko) | 2022-08-29 | 2025-04-23 | 다이이찌 산쿄 가부시키가이샤 | 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트 |
| TW202434307A (zh) * | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| EP4737483A1 (en) | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| TW202543683A (zh) * | 2024-02-28 | 2025-11-16 | 日商第一三共股份有限公司 | 抗egfr抗體-藥物結合物與其他劑之組合 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU2002311919B8 (en) | 2001-05-11 | 2007-03-22 | Ludwig Institute For Cancer Research Ltd | Specific binding proteins and uses thereof |
| IL161686A0 (en) | 2001-11-01 | 2004-09-27 | Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| US8809496B2 (en) | 2009-09-03 | 2014-08-19 | The Noguchi Institute | Production method of 11-sugar sialylglycopeptide |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| EP2934598B1 (en) | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2014189806A1 (en) | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| AU2014371934B2 (en) * | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| DE102014214408A1 (de) | 2014-07-23 | 2016-01-28 | Wacker Chemie Ag | Härtbare Organopolysiloxanzusammensetzungen |
| EP4530348A3 (en) | 2014-12-15 | 2025-08-06 | Basf Se | Detergent composition comprising subtilase variants |
| US11559581B2 (en) | 2015-01-09 | 2023-01-24 | Oxford University Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| JP2018534295A (ja) * | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| PT3440076T (pt) | 2016-04-07 | 2022-07-29 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas úteis como modeladores de proteína |
| WO2018003983A1 (ja) | 2016-07-01 | 2018-01-04 | 第一三共株式会社 | ｈＡＮＰ－Ｆｃ含有分子コンジュゲート |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| PT3523287T (pt) | 2016-10-04 | 2021-10-06 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting |
| US11001605B2 (en) | 2016-10-07 | 2021-05-11 | Biolog Life Science Institute Gmbh & Co. Kg | Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways |
| PE20210255A1 (es) * | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| EP3634401A1 (en) * | 2017-06-07 | 2020-04-15 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| EP3848054B1 (en) * | 2018-09-06 | 2025-01-29 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates of cyclic dinucleotide derivatives |
| TW202241454A (zh) * | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
-
2021
- 2021-03-05 IL IL296124A patent/IL296124A/en unknown
- 2021-03-05 NZ NZ791969A patent/NZ791969A/en unknown
- 2021-03-05 AU AU2021230226A patent/AU2021230226B2/en active Active
- 2021-03-05 MX MX2022009597A patent/MX2022009597A/es unknown
- 2021-03-05 EP EP21765256.9A patent/EP4115909A4/en active Pending
- 2021-03-05 TW TW113126643A patent/TWI906966B/zh active
- 2021-03-05 PH PH1/2022/551961A patent/PH12022551961A1/en unknown
- 2021-03-05 CA CA3168368A patent/CA3168368A1/en active Pending
- 2021-03-05 KR KR1020227033060A patent/KR20220151630A/ko active Pending
- 2021-03-05 WO PCT/JP2021/008635 patent/WO2021177438A1/ja not_active Ceased
- 2021-03-05 CN CN202180019047.0A patent/CN115209921B/zh active Active
- 2021-03-05 JP JP2022504474A patent/JPWO2021177438A1/ja not_active Ceased
- 2021-03-05 BR BR112022015283A patent/BR112022015283A2/pt unknown
- 2021-03-05 TW TW110108019A patent/TWI851879B/zh active
- 2021-03-05 US US17/908,381 patent/US20230330248A1/en active Pending
-
2022
- 2022-09-29 CO CONC2022/0013971A patent/CO2022013971A2/es unknown
-
2024
- 2024-11-27 JP JP2024206626A patent/JP2025023046A/ja active Pending
-
2025
- 2025-09-19 AU AU2025234261A patent/AU2025234261A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021177438A5 (https=) | ||
| JP7146031B2 (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート | |
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| RU2711640C2 (ru) | Конъюгат анти-her3 антитело-лекарственное средство | |
| KR20240082348A (ko) | 항체, 이의 항체-약물 접합체 및 이의 용도 | |
| JP2022515318A5 (https=) | ||
| JP2022549344A5 (https=) | ||
| JP2021515559A5 (https=) | ||
| WO2015146132A1 (ja) | 抗ｃｄ９８抗体－薬物コンジュゲート | |
| JP2017506217A (ja) | 標的ＴＧＦβ阻害 | |
| KR20150042751A (ko) | Pd-l1에 결합하는 항원 결합 단백질 | |
| JP2023548522A (ja) | 免疫チェックポイント阻害剤と抗体－アマトキシンコンジュゲートの組合せを含む癌治療に使用するための組成物 | |
| JP2024054123A (ja) | 癌の治療のための配合剤 | |
| TWI763956B (zh) | 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法 | |
| JP7302793B2 (ja) | Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法 | |
| WO2023163087A1 (ja) | 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬 | |
| TW202543683A (zh) | 抗egfr抗體-藥物結合物與其他劑之組合 | |
| RU2784604C2 (ru) | Комбинированная терапия из антитела к прогастрину и иммунотерапии для лечения рака | |
| WO2025232773A1 (zh) | 药物组合及其用途 | |
| WO2025164597A1 (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲートと他剤との組み合わせ | |
| JP2025538377A (ja) | 抗ｉｌ－２抗体の使用方法 | |
| JP2025088767A (ja) | ＰＳＭＡ－ＳＴＥＡＰ１二重可変ドメイン免疫グロブリン（ＤＶＤ－Ｉｇ）分子及び薬物コンジュゲート | |
| JP2024540536A5 (https=) | ||
| TW202612743A (zh) | 抗體-藥物結合物之用途 |